Oncomed Pharmaceuticals (NASDAQ:OMED) is set to issue its quarterly earnings data after the market closes on Wednesday, February 21st. Analysts expect the company to announce earnings of ($0.35) per share for the quarter.
Oncomed Pharmaceuticals (NASDAQ OMED) opened at $2.25 on Tuesday. The stock has a market cap of $85.18, a P/E ratio of -1.19 and a beta of 2.24. Oncomed Pharmaceuticals has a 1 year low of $1.74 and a 1 year high of $10.89.
OMED has been the topic of a number of research reports. Zacks Investment Research upgraded shares of Oncomed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.50 target price on the stock in a research report on Wednesday, November 8th. Cantor Fitzgerald set a $6.00 target price on shares of Oncomed Pharmaceuticals and gave the stock a “hold” rating in a research report on Thursday, January 4th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and two have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $5.81.
TRADEMARK VIOLATION NOTICE: “Oncomed Pharmaceuticals (OMED) to Release Earnings on Wednesday” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/20/oncomed-pharmaceuticals-omed-to-release-earnings-on-wednesday.html.
About Oncomed Pharmaceuticals
OncoMed Pharmaceuticals, Inc (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11).
Receive News & Ratings for Oncomed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncomed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.